Company Overview of Philogen S.p.A.
Philogen S.p.A., a biotechnology company, is engaged in the discovery and development of biopharmaceutical products for the treatment of certain diseases that are characterized by angiogenesis, the proliferation of newly formed blood vessels. The company focuses on delivering bioactive agents, such as cytokines, radionuclides, or drugs to the site of disease using antibodies and ligands that specifically target stromal antigens. It develops anti-cancer antibody derivatives and antibody-derivatives for the treatment of rheumatoid arthritis. Its products include DARLEUKIN (L19-IL2), Teleukin, and Fibromun (L19-TNF) that are human vascular targeting immunocytokine. The company also develops L19...
Via Bellaria, 35
Sovicille, SI 53018
Founded in 1996
Key Executives for Philogen S.p.A.
Vice President and Director
Compensation as of Fiscal Year 2014.
Philogen S.p.A. Key Developments
Philogen S.p.A. Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013
Feb 7 13
Philogen S.p.A. Presents at EBD Group's 7th Annual BIO-Europe Spring Conference 2013, Mar-11-2013 . Venue: Centre Covencions International Barcelona, Plaça de Willy Brandt, 11-14, 08019 Barcelona, Spain.
Actinium Pharmaceuticals, Inc. and Philogen S.P.A. Announce Start of Pre-Clinical Development of an Alpha Therapy Based Antiangiogenesis Program
Nov 29 12
Actinium Pharmaceuticals, Inc. and Philogen S.p.A. announced that they have commenced pre-clinical development of Philogen's L19 antibody construct labeled with actinium 225 as a therapeutic payload. The L19 antibody targets newly formed blood vessels that otherwise allow cancers to grow. Clinical trials of drug candidates based on alpha emitting isotopes have so far demonstrated significant efficacy with minimal side effects in blood borne cancers, in metastases of solid cancers and in residual disease in solid cancers post-surgery. Actinium Pharmaceuticals and Philogen intend to add antiangiogenesis to this growing field of use of alpha emitters. Antiangiogenesis is a successful approach to treating numerous cancer types. Currently approved antiangiogenesis drugs act mostly by interfering with the signaling pathway used by cancer cells to stimulate growth of blood vessels. In many cases, cancer cells eventually find alternative ways to spur blood vessel growth. In contrast, Philogen's L19 targets adhesion molecules that anchor blood vessel cells which makes it less susceptible to cancer controlled pathways. Depending on the architecture of vasculature and its proximity to cancer stem cells, actinium 225 coupled with L19 could potentially offer an effective combination of properties tailor made for certain solid cancer types. The first model under consideration is glioblastoma multiforme, a difficult to treat form of brain cancer.
Philogen S.p.A. Presents at BIO-Europe 2012, Nov-12-2012
Nov 9 12
Philogen S.p.A. Presents at BIO-Europe 2012, Nov-12-2012 . Venue: CCH Congress Center Hamburg, Am Dammtor / Marseiller Str, 20355 Hamburg, Germany.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|